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Abstract
Background: Myostatin is a potent muscle growth inhibitor that belongs to the Transforming Growth Factor-b
(TGF-b) family. Mutations leading to non functional myostatin have been associated with hypermuscularity in
several organisms. By contrast, Duchenne muscular dystrophy (DMD) is characterized by a loss of muscle fibers and
impaired regeneration. In this study, we aim to knockdown myostatin by means of exon skipping, a technique
which has been successfully applied to reframe the genetic defect of dystrophin gene in DMD patients.
Methods: We targeted myostatin exon 2 using antisense oligonucleotides (AON) in healthy and DMD-derived
myotubes cultures. We assessed the exon skipping level, transcriptional expression of myostatin and its target
genes, and combined myostatin and several dystrophin AONs. These AONs were also applied in the mdx mice
models via intramuscular injections.
Results: Myostatin AON induced exon 2 skipping in cell cultures and to a lower extent in the mdx mice. It was
accompanied by decrease in myostatin mRNA and enhanced MYOG and MYF5 expression. Furthermore,
combination of myostatin and dystrophin AONs induced simultaneous skipping of both genes.
Conclusions: We conclude that two AONs can be used to target two different genes, MSTN and DMD,i na
straightforward manner. Targeting multiple ligands of TGF-beta family will be more promising as adjuvant therapies
for DMD.
Background
Duchenne muscular dystrophy (DMD) is an X-linked
recessive neuromuscular disorder, which is caused by
dystrophin deficiency in muscle fibers. DMD fibers are
more sensitive to muscle damage, leading to degenera-
tion and replacement of muscle fibers by fat and con-
nective tissue (fibrosis). Monaco et al found that frame
shift mutations in the DMD gene will lead to a trun-
cated and non-functional form of dystrophin [1], which
become the primary cause of the disease. However,
mutations which maintain the DMD open reading frame
result in shorter dystrophin proteins that retain the
essential actin binding-, cysteine rich- and carboxy
terminal domains, and thus are partly functional [1].
Patients with such mutations develop the less severe
Becker muscular dystrophy. This reading frame rule
holds true for ~91% of DMD cases [2] and has inspired
the development of the exon skipping strategy, which
employs antisense oligonucleotides (AONs). These small
synthetic RNA molecules are complimentary to exonic
or splice site sequences, thereby upon hybridization are
able to modulate exon inclusion by the splicing machin-
ery (recently reviewed in [3-5]).
Comprehensive studies done by our group and others
have provided the proof of principle of the therapeutic
feasibility of the AON to reframe dystrophin transcripts
and restore dystrophin synthesis, both in vitro [6-8] and
in vivo using the mdx and hDMD mice [9-11]. Subse-
quent clinical trials have shown that two different AON
chemistries, either 2’-O-methyl phosphorothioate
(2’OMePS) [12] or phosphorodiamidate morpholino oli-
gomer (PMO) [13] targeting DMD exon 51 can restore
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minimum side effect.
However, other major facets of DMD pathology which
include severe muscle wasting, fibrosis and flawed mus-
cle regeneration may reduce the efficacy of the DMD
exon skipping therapy. In addition, as DMD patients
suffer from muscle degeneration from their early life,
myoblasts undergo extensive division in an attempt to
regenerate, which eventually leads to exhaustion of the
muscle regenerative potential [14-16]. Therefore, several
additional therapies have been considered to overcome
these problems, in which myostatin inhibition has
received considerable interest.
Myostatin or Growth and Differentiation Factor-8
(GDF-8), an evolutionary conserved TGF-b family mem-
b e rt h a ti se x p r e s s e dp r e d o m i nantly in skeletal muscle,
is a potent muscle growth inhibitor. Natural mutations
or targeted knockdown in the MSTN genes, which lead
to non-functional proteins are associated with hyper-
muscularity in several organisms such as mice, cattles,
dog, horse, sheep and human [17-21]. Myostatin signal-
ing requires binding to the Activin type IIB receptor
(AcvRIIb) and Activin receptor-like kinase 4/5 (ALK4/5)
receptor complex and subsequent phosphorylation of
downstream Smad2 and Smad3 [22], which further
influences myogenesis through transcriptional regulation
of cell cycle and myogenic regulatory factors [23-27].
Several strategies to block myostatin such as neutraliz-
ing antibodies [28-30], overexpression of its inhibitory
propeptide [31-34], or administration of soluble AcvRIIB
[35] induced increases in muscle mass and force and
reduced fibrosis in the mdx mice [36].
A recent study by Dumonceaux et al [37] targeted
the myostatin receptor AcvRIIb using shRNA and
coupled it with a modified U7 small nuclear RNA to
restore dystrophin in single adeno-associated vectors
(AAV). This study showed that combination therapy has
an added value in improving muscle physiology. How-
ever, as recently reviewed by Tang et al [38], one major
limitation of AAV-based gene therapy approach is the
immune response against the vector and/or transgene.
In this study we chose to use 2’OMePS AON to target
MSTN exon 2 and disrupt its translational reading
frame in order to knockdown its expression level. As it
harbors the same chemistry modification as the PRO051
DMD AON currently in trial, we hypothesized that the
administration of the two AONs as a cocktail would be
achievable and may thus yield a combination treatment
by simultaneously correcting the Dmd transcript and
downregulating the Mstn transcript. In addition, as
recently reviewed in [39], the 2’OMePS modification
enhances the stability and increases the in vivo half-life
compared to the previously studied butanol-tagged anti-
sense [40] or siRNA-mediated RNA interference
approaches targeting myostatin [41]. We evaluated its
feasibility to induce exon skipping and downregulate
MSTN expression in myotubes cultures and DMD
mouse models. Furthermore, we combined it with sev-
eral DMD AONs to look into the possibility of skipping
two genes simultaneously (Figure 1).
Methods
Antisense oligonucleotides
AON with phosphorothioate backbones and 2’-O-methyl
ribose modifications used in this study were synthesized
and high-pressure liquid chromatography purified by
Eurogentec, Belgium. The sequences are listed in Table 1.
Cell culture
Human primary myoblasts obtained from a healthy donor
(KM109) [42], immortalized myoblast cell line (7304-1)
generated by expressing telomerase (hTERT) and cyclin-
dependent kinase 4 [43], and DMD patient derived myo-
blasts with a deletion in exon 51-55 (DL589.2) [7] were
used in this study. All of the cells mentioned above were
seeded on thin layer collagen (1:30, PureCol, Inamed Bio-
materials, Fremont). The primary cells were grown in Nut.
Mix F-10 (HAM) supplemented with GlutaMax-I, 20%
Fetal Bovine Serum (FBS) and 1% Penicillin/Streptomycin
(Gibco-BRL) at 37°C, 5% CO2. The 7304-1 cells were cul-
tured in Skeletal Muscle Cell Basal Medium supplemented
with 15% FBS, 5 μg hEGF, 0.5 μg hFGF, 25 mg Fetuin, 5
mg Insulin and 200 μg Dexamethasone (PromoCell
GmbH, Germany). 80-90% confluent culture was induced
to differentiate into myotubes in DMEM supplemented
with 2% FBS, 1% P/S, 2% Glutamax and 1% glucose
(Gibco-BRL), except the 7304-1 in which 2% of Horse
Serum was added instead of FBS.
AON transfections
Myotubes were transfected with different dilutions
of AON in 0.15 M NaCl using 2.5 μl polyethylenimine
(ExGen 500, MBI Fermentas) per μg of AON for 3 hours.
Animals and AON injections
All experiments were performed with 5-6 weeks old
mdx mice under the approval of the Animal Experimen-
tal Committee (DEC07195) of the LUMC. In the single
injection experiments, the AONs were administered into
the gastrocnemius muscle at the dose of 40 μg per injec-
tion in 50 μl physiological salt. Control DMD AON
(M23D) was injected in the contralateral muscle. After 4
days, the mice (n = 2) were sacrificed and muscles were
isolated, snap frozen and sectioned at three different
positions (proximal, medial and distal relative to the
tendon) for total RNA isolation.
In the consecutive injections experiments, cocktails of
MSTN or control AONs with M23 DMD AON were
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gastrocnemius muscle. Four consecutive injections were
performed with a 48 hours resting time between the
second and third injection. The mice (n = 6) were sacri-
ficed at 6 hours, 1 and 2 days after the last injection.
The muscles were isolated, snap frozen and sectioned.
Pool of sections from different area of the muscles was
collected for RNA isolation.
RNA Isolation, RT-PCR and Quantitative PCR analysis
Cell lysates were prepared using lysis buffer provided in
the NucleoSpin RNA II kit (Macherey-Nagel, Germany)
Table 1 Antisense oligonucleotides used in this study
AON Targeting Sequences (5’-3’)
AON1 Myostatin exon 2 guuugaugagucucaggauu
AON2 Myostatin exon 2 gccaaauaccagugccu
AON3 Myostatin exon 2 agccaauuuugcaacacugu
h8AON3 Human dystrophin exon 8 guacauuaagauggacuuc
h44AON1 Human dystrophin exon 44 cgccgccauuucucaacag
h51AON1 Human dystrophin exon 51 ucaaggaagauggcauuucu
h54AON1 Human dystrophin exon 54 uacauuugucugccacugg
M23D (+02-18) Mouse dystrophin exon 23 ggccaaaccucggcuuaccu
1 2       3
1      2 3
Sig Mature Propeptide
Pre-
mRNA
mRNA
protein
1 2       3
1          3
Sig Propept
AON
*
Actin
binding Central rod Cys
rich C-term
?
Actin
binding Central rod
*
Actin
binding Central rod
Cys
rich C-term
?
AON
A
B
C
E D
Figure 1 Schematic overview of myostatin and dystrophin exon skipping. The myostatin gene (MSTN) consists of three exons, whereas the
protein consists of three domains: signaling (sig.), propeptide and mature domains. The position of each exon relative to each domain is
denoted by broken lines (A). Antisense oligonucleotides (AON) targeting exon 2 will hybridize and hide the exon from the splicing machinery,
resulting in skipping exon 2 upon mRNA splicing. The removal of exon 2 will disrupt the open reading frame (ORF; *) and the protein will lack
part of the propeptide and the entire mature domain (B). Dystrophin gene (DMD) consists of 79 exons, whereas the proteins consist of actin
binding-, central rod, cysteine rich- and C-terminal domains (C). One of the examples of DMD is deletion in exon 48-50 which disrupted the
reading frame and introduces premature stop codon (*). Due to this mutation, part of the central rod and the entire Cys-rich and C-terminal
domains are missing (D). In the therapy (currently in clinical trials), AON is directed towards exon 51. With the similar principle, exon 51 will be
skipped upon mRNA splicing which in turn restores the ORF. This internally-deleted DMD will be translated as dystrophin with shorter central
rod domain. However, since the essential C-terminal domain is retained, the protein is partially functional (E).
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Page 3 of 10and RNA was isolated using the same kit according to
manufacturer’s instructions. Sectioned muscles were
initially lysed using the same buffer and crushed with
MagNA Lyser Green beads in the MagNA Lyser instru-
ment (Roche Diagnostics, Germany) at 7000 oscillation
speed for 2 × 20 seconds. RNA was isolated using the
same procedure. The RNA quantity and integrity were
measured using RNA 6000 Nanochip in the Agilent
2100 bioanalyzer (Agilent Technologies). cDNA was
synthesized from 500 ng of RNA using RevertAid H
Minus M-MuLV Reverse Transcriptase (MBI Fermentas)
with 40 ng of random hexamer primer, according to the
manufacturer’s instructions. 10× diluted cDNA was then
amplified by PCR using primers listed in Table 2. Myos-
tatin amplifications were performed at 94°C (30 s), 56°C
(30 s), 72°C (60 s) for 30 cycles. Dystrophin PCRs were
performed in two rounds. The first PCR was performed
by 20 cycles of 94°C (40 s), 60°C (40 s), 72°C (80 s). 1.5
μl of these reactions were then reamplified in nested
PCRs by 32 cycles of 94°C (40 s), 60°C (40 s), 72°C (60
s). Quantitative PCRs were carried out in a 384-wells
plate with 2 μl of 10X diluted cDNA, 1 μlo f1p m o l / μl
forward primers, 1 μl of 1 pmol/μl reverse primers and
6 μlo fi Q ™ SYBR
® Green Supermix (Bio-Rad) in Light-
Cycler 480 (Roche Diagnostics, Germany). Each measure-
ment was performed in triplicates. Expressions of the
genes of interest were normalized to housekeeping gene
GAPDH a n da n a l y z e du s i n gΔΔCt method with Gene
Expression Analysis for iCycler iQ
® Real-Time PCR
Detection System software developed by Bio-Rad.T h e
expression values of 3-4 biological experiments were
averaged. For the statistical analysis, the expressions in
MSTN AON-transfected samples were compared to 500
nM control AON transfected samples in Student’s t-test.
P-values < 0.05 were considered significant.
Results
Myostatin AON induces exon 2 skip in vitro
Based on previously described guidelines [44], we
designed three AONs targeting different regions in
MSTN exon 2 gene and used previously designed AONs
targeting DMD exons as controls (Table 1). All AONs
consisted of 2’-O-methyl RNA and had a phosphor-
othioate backbone in order to resist endonucleases and
RNaseH degradation. We evaluated their efficiency
using immortalized human myoblasts (7304-1) as well
as primary myoblasts from a healthy individual (KM109)
and a DMD patient with a deletion in exon 51-55
(DL589.2). We used differentiated myotube cultures
because the expression levels of myostatin and dystro-
phin were found to be higher in the differentiation than
in proliferation stage (data not shown).
To examine the feasibility to induce myostatin exon 2
skipping, different concentrations of each AON were
transfected into the myotube cultures using the cationic
polymer polyethylenimine (PEI). More than 80% of the
cells showed specific nuclear uptake upon transfection
with 5’-fluorescein (FAM)-labeled control AON (Figure
2A). RT-PCR performed two days post transfection (Fig-
ure 2B) and subsequent sequencing analysis (Figure 2C)
showed the exclusion of exon 2 from the myostatin
transcript in the myostatin AON-transfected cells,
resulting in a premature stop codon formation. This
internally truncated fragment was not observed in any
of the non-transfected and control AON-transfected
myotubes. One myostatin AON, namely AON1, gave
the most consistent and highest skipping efficiency
[Additional file 1]. Thus we further used the AON1
(addressed as myostatin AON from now on) and con-
firmed its exon skipping ability in human and to a lower
extent in mouse cells models, using its perfect comple-
mentary to the human and mouse MSTN sequences
(Figure 2B and not shown).
AON-mediated exon skipping decreased myostatin
transcript expression level and increased expression of
myogenic regulatory factors
Next, we determined the expression level of MSTN
transcript upon exon skipping by quantitative real time
P C R .W eu s e dp r i m e r si ne x o n1a n de x o n2 ,t h e r e b y
detecting only the non-skipped products. As shown in
Figure 2D, the levels of full length MSTN transcript
Table 2 Primers used in this study
Primers Sequences Used for
Mstn Ex1F GGAAACAGCTCCTAACATCAG Myostatin exon 2 skip
PCR
Mstn Ex3R CTGAGCAGTAATTGGCCTTATATC
Mstn
Ex1F1
GATGACGATTATCACGCTAC Myostatin QPCR
Mstn
Ex2R1
GCACAAACACTGTTGTAGGA
Myog Fw GCCAGACTATCCCCTTCCTC Myogenin QPCR
Myog Rev AGGGATGCCCTCTCCTCTAA
Myf5 Fw CCACCTCCAACTGCTCTGAT Myf5 QPCR
Myf5 Rev GCAATCCAAGCTGGATAAGG
Gapdh Fw CAATGACCCCTTCATTGACC Gapdh QPCR
Gapdh Rev GACAAGCTTCCCGTTCTCAG
DMD Ex6F CTGGCTTTGAATGCTCTCATC DMD exon 8 skip PCR
DMD
Ex11R
GCTGTCAAATCCATCATGTACC
DMD
Ex42F
GTGATGACTGAAGACATGCC DMD Exon 44 skip PCR
DMD
Ex45R
TCTGTCTGACAGCTGTTTGC
DMD
Ex53F
TTCAGAATCAGTGGGATGAAG DMD Exon 54 skip PCR
DMD
Ex56R
CGTCTTTGTAACAGGACTGC
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Page 4 of 10decreased significantly in the myostatin AON-trans-
fected samples, with slight variations in the knockdown
levels between different cells. Notably, these decreases
were achieved in an inverse dose-dependent manner,
meaning that the most pronounced knockdown was
achieved with 100 nM AON, which was the lowest
concentration of myostatin AON tested. This effect
was seen especially in the KM109 cells. In addition,
the control AON induced less pronounced but still sig-
nificant decreases of the full-length MSTN levels in
some cells (7304-1 and DL589.2) (Figure 2D), which
might be due to the transfection. Therefore, the
expression levels in myostatin AON-transfected sam-
ples were compared with those in the control AON-
transfected samples.
As outlined in Figure 1B, myostatin skipping results in
premature stop codon in exon 3 and thus non-func-
tional myostatin protein. Several studies have described
that myogenic cells respond to myostatin by down-regu-
lating the expression of key transcriptional regulators of
muscle development such as Pax3, Pax7, p21, MyoD,
Myf5 and Myog [23-27,45,46], explaining its inhibitory
effects in differentiation. Therefore, inhibition of myos-
tatin should lead to an increased expression of these
myogenic regulators and thus can be used as a func-
tional readout of the myostatin knockdown. Corre-
spondingly, knockdown of myostatin in differentiated
myotubes cultures resulted in a consistent upregulation
of MYF5 and MYOG expression (Figure 3A and 3B).
The fold increase varied between 3-12 fold and depen-
dent on the myoblast cultures used, which may reflect
the different myogenic differentiation potential of the
different myoblast cultures.
Dual exon skipping in MSTN and DMD in control and
DMD patient derived myotubes
Our ultimate goal was to use AONs to simultaneously
reframe the mutation in the DMD gene and to downre-
gulate MSTN expression in order to correct the primary
genetic defect as well as to enhance muscle regenera-
tion. Therefore, we combined the myostatin AON with
several DMD AONs used in the previous studies
[6,7,47]. We specifically applied DMD AONs covering
the hotspot mutated regions in DMD gene, namely
h8AON3, h44AON1, h51AON1 and h54AON1 (Table
1) in control myotubes cultures (primary (KM109) or
immortalized myoblasts (7304-1)). Myotubes were trans-
fected with either myostatin or DMD AONs or a mix of
both. As shown in Figure 4, MSTN exon skip was
observed in all myostatin AON-transfected samples,
regardless of the presence of DMD AON. Vice versa, all
DMD AON-transfected myotubes showed the exon-spe-
cific dystrophin skips described before [6,7,47], regard-
less of the presence of MSTN AON. To investigate the
possibility that the two AONs hybridized to each other
rather than to their intended target, we varied the trans-
fection conditions by mixing the AON before complex-
ing with PEI, or preparing the AON-PEI complexes
separately. However, no difference in their efficiency to
induce skipping was found. We observed skipping with
the total AON concentration of 200 nM (Figure 4) as
well as 100 nM (not shown). These results demonstrated
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differentiation
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Figure 2 M y o s t a t i ne x o n2s k i pi ns e v e r a lm y o t u b e sc u l t u r e s . Human primary control (KM109) and DMD patient derived- (DL589.2)
myoblasts were differentiated for 7 days before transfection with MSTN AON. Immortalized control (7304.1) myoblasts were differentiated for 2-3
days. A non-targeting, fluorescently-labeled AONs were transfected as control. Fluorescent nuclei were observed three hours post-transfection
(A). RNA was isolated 2 days post-transfection. cDNA was synthesized using random hexamer (N6) primers and subjected for PCR using primers
in exon 1 and 3 (B). Note the inverse dose-dependent skips in KM109 samples. Skip fragment was confirmed by sequencing analysis (C).
Quantitative real-time PCR was performed using primers in MSTN exon 1 and 2, thereby depicting the expression of remaining full length or
non-skipped transcript (D). Data are means ± SD from 3 to 4 independent experiments. Expression was normalized with GAPDH. Statistical
analysis was performed using Student’s t-test, using the 500 nM control AON-transfected samples as reference. *P < 0.05
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Page 5 of 10the feasibility of simultaneous antisense-mediated skip-
ping of exons of two different genes.
To further assess its therapeutic potential, we per-
formed dual exon skipping in the DL589.2 cells, which
were derived from a DMD patient with an exon 51-55
deletion. Our previous study has shown that the reading
frame can be corrected by an exon 50 skip upon trans-
fection with h50AON1 [7]. As shown in Figure 5, com-
bining this AON with the myostatin AON showed clear
targeted skipping of both DMD and MSTN.
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Figure 3 The expression myogenic regulatory factors MYOG and MYF5 upon exon 2 skipping. Cells were fused and transfected with
different concentrations of AON as described in Figure 2. Total RNA was isolated and N6-primed cDNA was subjected to quantitative real-time
PCR for MYOG (A) and MYF5 (B). Data are means ± SD from 3 to 4 independent experiments. Expression was normalized with GAPDH. Statistical
analysis was performed using Student’s t-test, using the 500 nM control AON-transfected samples as reference. *P < 0.05
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Figure 4 Dual exon skipping of myostatin and dystrophin in control cells. KM109 (A) and 7304-1 (B) myotubes were transfected with 200
nM of myostatin AON and AON targeting different DMD exons, namely exon 8, 44 and 54. The AONs were premixed (boxed) before
complexing with the transfection reagent, or directly complexed (not boxed). RNA was isolated two days post-transfection and analyzed for
myostatin or dystrophin skips by RT-PCR.
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We subsequently examined the ability of myostatin
AON to induce exon skipping in the mdx mouse model.
Myostatin AON was injected at a dose of 40 μg/injec-
tion into the gastrocnemius muscle of the mdx mice.
D M DA O Nt a r g e t i n ge x o n2 3( M 2 3 D ,p r e v i o u s l y
denoted as M23D(+02-18) [9]) was injected into the
contralateral muscle. This AON served as a positive
control and was shown by many different groups includ-
ing ours [9,11] to induce efficient and robust exon skip-
ping. The mice were sacrificed at four days after
injection. We classified different sections of the muscles
as the proximal (P), medial (M) and distal (D) relative
to the tendon and observed heterogenous patterns of
Mstn exon 2 skips (Figure 6A). The skipping levels in
the proximal and medial parts of the muscles were
higher than in the distal, while Dmd skips appeared to
be heterogenous throughout the muscles.
Our previous study in dystrophin exon skipping had
indicated that higher skipping efficiencies could be
obtained by multiple injections of the AON. In order to
increase the efficiency of the myostatin AON and to
answer whether dual skipping can be achieved in vivo,
we injected cocktails of M23D DMD AON with myosta-
tin or control AONs once a day for four times, with a
48 hours resting time between the second and third
injections. RT-PCR analysis was performed from RNA
isolated from proximal, medial and distal parts of the
muscle (Figure 6B). 6 hours after the last injection, we
already observed weak myostatin skip in one of the two
injected muscles. At the later time points, the skipping
levels modestly increased, suggesting a trend of accumu-
lations of skipping over time. Conversely, the Dmd skips
showed relatively more stable and more importantly
higher skipping levels.
Discussion
DMD patients suffer from progressive muscle wasting
due to the absence of functional dystrophin protein.
The AON-mediated exon skipping therapy has been
shown to successfully reframe the mutated DMD gene
and restore local dystrophin synthesis in DMD patients
[12,13]. This approach is currently viewed as one of the
most promising therapeutic approaches for DMD. How-
ever, it targets dystrophin transcripts, which are pro-
duced only in muscle and not in adipose and fibrotic
49 56 50 57
49  56  57
123
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-       +      -       +      +      +     +
+      -       +      -       +      +     +
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100 bp
Figure 5 Dual exon skipping of myostatin and dystrophin in
DL589.2 DMD patient cells. DL589.2 myotubes were transfected
with 200 nM of myostatin AON and h50AON1 DMD AON. RNA was
isolated two days post-transfection and analyzed for myostatin and
dystrophin skips by RT-PCR.
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Figure 6 Administration of myostatin AON in mdx mice.S i n g l e
dose of 40 μg MSTN AON was injected into the gastrocnemius
muscles of mdx mice. Control M23 DMD AON were injected in the
contralateral muscles. The animals were sacrificed 4 days after
injection. RNA was isolated from three different parts of the muscles
relative to the tendon: proximal (P), medial (M) and distal (E). RT-PCR
analysis was performed to detect dystrophin (upper) or myostatin
(lower) skips (A). Four times consecutive injections were performed
with cocktails of AON containing 40 μg of m23 DMD AON and 40
μg of either myostatin or control AON into the gastrocnemius
muscles of mdx mice. Injections were varied between contralateral
muscles. The mice were sacrificed at 6 hours, 1 day and 2 days after
the last injection. RNA was isolated from multiple areas within the
muscles and analyzed for dystrophin (upper) or myostatin (lower)
skips by RT-PCR (B).
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regeneration or reduce fibrosis levels. To address both
the underlying genetic defect and the loss of muscle, we
here explored the possibility of using AONs to inhibit
myostatin expression and AONs to reframe dystrophin
transcripts simultaneously.
Our results show that the second exon of the MSTN
gene can be skipped in multiple myotube cultures, either
derived from healthy individuals, DMD patient or mouse.
The removal of exon 2 disrupts the open reading frame
and introduces premature stop codon. We observed
downregulation of myostatin transcript levels up to 50-
80%, depending on the type of cells tested. One can
expect the truncated transcripts to be degraded via non-
sense mediated decay, thus not being translated into pro-
teins. Nonetheless, we observed a clear skip product in
the RT-PCR analysis, suggesting that the transcript might
be fairly stable. However, the premature stop codon
introduced will result in truncated myostatin protein that
lacks ~25% of the propeptide and the entire mature
domains, which will abrogate its downstream signaling.
The effects of interventions with myostatin expression
in muscle differentiation were assessed by increased
expressions of MYF5 and MYOG. Although the expres-
sion levels of these genes were increased in all samples
transfected with MSTN AON, there was no clear corre-
lation between the fold decrease of MSTN and the fold
increase of MYF5 and MYOG. One explanation for this
observation could be that a threshold effect of myostatin
knockdown on the expression of these genes is already
attained when the MSTN transcript is slightly downre-
gulated. However, the fact that we observed the upregu-
lation of these genes in three to four independent
experiments using different myoblasts suggests that this
effect of myostatin downregulation using MSTN AON
is valid and reproducible.
Finally, the mix of myostatin and dystrophin AONs
showed that skipping two genes is feasible without inter-
fering each other. The experimental set up was varied by
mixing the AONs before complexing with the transfec-
tion reagent, or by preparing complex of AON and
transfection reagent separately before mixing with each
other to rule out the possibility that two AONs hybri-
dize to each other. There seems to be no difference in
the skipping efficiency, regardless if both AON were
pre-mixed or not. However, we recommend to check
the hybridization-likelihood by verifying the sequences
of both AONs using freely available software tools such
as RNAstructure [48].
One less encouraging finding was considerably low
Mstn skipping level in vivo compared to the cultured
cells. The M23D dystrophin AON, which was injected
as a control in the contralateral muscle resulted in
higher dystrophin skipping efficiency, confirming that
the AON was injected properly. Repeated injections
only showed modest improvements in the exon skipping
level of myostatin. We also observed heterogenous skip-
ping patterns throughout the muscles which seem to be
specific for Mstn and not Dmd. We offer two reasons to
explain the low myostatin skipping in vivo. First, we
noted that the myostatin exon skipping efficiency in
mouse cells was lower than in human cells in vitro.
Thus, there is a possibility of species-dependent differ-
ences in the efficiency of our myostatin AON, although
the AON was designed for both human and mouse.
Another explanation might be that myostatin is also
expressed in muscle satellite cells and fibroblasts. In
vitro, we indeed saw higher MSTN expression in pri-
mary cultures containing mix populations of fibroblasts
and myoblasts than in immortalized myoblasts. We pre-
viously demonstrated that the leaky muscle membrane
facilitates the AON to enter the muscle fibers, where
dystrophin is predominantly expressed, thus explaining
the high efficiency of dystrophin AON. The delivery of
the AON to fibrotic area and satellite cells, where myos-
tatin is also expressed will presumably be more difficult.
Furthermore, a recent study by Kang et al [49] which
also targeted myostatin exon 2 showed efficient exon
skipping in vivo using octa guanidine morpholino oligo-
mers. The chosen chemistry seems to be the key to
facilitate the delivery and thereby inducing prominent
exon skipping in vivo. Finally, several studies have
shown that members of the TGF-beta family other than
myostatin are responsible in inhibiting muscle differen-
tiation [35,50,51]. Therefore, as a future prospective, tar-
geting multiple ligands seems to be a more promising
strategy, especially when combined with dystrophin
restoration.
Conclusions
In conclusion, our results provide a rationale for the use
of two AONs targeting two different genes and further
extend the versatility of exon skipping-based therapy.
The efficiency and delivery techniques remain to be
improved, especially for further in vivo studies. While
the correction of genetic defect is essential, combination
with other adjuvant therapies which do not rely solely
on myostatin inhibition, but also other TGF-beta family
members regulating muscle differentiations might be
more beneficial for DMD therapies.
Additional material
Additional file 1: Human primary control (KM109) myoblasts were
differentiated for 7 days before transfection with 3 different MSTN
AONs at 500 and 100 nM concentrations. All AONs were designed to
target exon 2 of the myostatin gene. The sequences are listed in table 1.
RNA was isolated 2 days post-transfection. cDNA was synthesized using
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exon 1 and 3.
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